Key Points
- Regeneron director Huda Zoghbi sold 800 shares for approximately $640,000 at $800 per share, reducing her holdings by 31.96%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Regeneron reported a strong quarter, with EPS of $14.29 versus the $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year.
- Analysts maintain a generally positive view, with the stock holding a “Moderate Buy” consensus rating and a $797.75 average price target; however, the company faces potential litigation related to its failed fianlimab-Libtayo melanoma trial.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director owned 603 shares of the company's stock, valued at $482,400. This represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Regeneron Pharmaceuticals Trading Up 0.1%
NASDAQ:REGN opened at $797.99 on Thursday. The company has a market cap of $82.16 billion, a P/E ratio of 19.72, a P/E/G ratio of 1.36 and a beta of 0.22. The stock's fifty day moving average price is $668.89 and its two-hundred day moving average price is $713.34. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the business earned $12.81 earnings per share. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.
Key Headlines Impacting Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Analyst commentary highlights continued growth from Eylea HD and Dupixent, along with progress in oncology and Regeneron’s broader pipeline. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
- Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, reinforcing a constructive view of the company’s long-term prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
- Neutral Sentiment: Directors Huda Y. Zoghbi and Kathryn Guarini each sold shares at approximately $800 under pre-arranged Rule 10b5-1 trading plans. The transactions reduced their holdings by about 32% and 40%, respectively, but the plans lessen the signal that the sales reflect current views of Regeneron’s outlook. Director Sale Filing
- Negative Sentiment: Several law firms publicized a securities class action related to alleged investor harm and claims that Regeneron misled investors about the prospects of its Phase 3 fianlimab-Libtayo trial in advanced melanoma. The trial failure previously caused an approximately $11 billion market-value loss; the legal notices could sustain concern about litigation costs, disclosure practices and the oncology pipeline. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit Notice
Hedge Funds Weigh In On Regeneron Pharmaceuticals
Several large investors have recently added to or reduced their stakes in REGN. WPG Advisers LLC increased its stake in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have commented on REGN shares. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Citigroup lifted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating for the company in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $797.75.
View Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
